Computer File

MERCK: COVID-19 VACCINES

---

COVID-19 infections were still climbing across the U.S. and many other parts of the world in September 2020, and it seemed that every time Ken Frazier, the CEO of Merck & Co. consented to an interview in recent months he always seemed to hear the same question, "Where's Merck?" The company, a leader in the global vaccine business had a low public profile even though it was working assiduously on two vaccine candidates for the SARS-CoV-2 virus that causes COVID-19. The U.S. Government had initiated a high profile program-Operation Warp Speed (OWS)-to accelerate the development of vaccines, but Merck was notably absent. Should Merck seek or accept funding from OWS, and what terms might accompany such an agreement?

---

Availability

CS621028

CS621028

RLC MM (Server RLC)

Available

Detail Information

Series Title

Case Study

Statement of Responsibility

Willy C. Shih

Call Number

CS621028

Publisher

Boston : Harvard Business Publishing., 2020

Collation

28 p. ; 2.3 mb.

Language

English

ISBN/ISSN

621028-PDF-ENG

Classification

658

Content Type

PDF File

Edition

-

Subject(s)

Manajemen Stratejik
Case Study
Covid-19
Innovation
Corporate Strategy
R&D
Operations
Supply Chain Management

Specific Detail Info

Kontak RLC untuk mendapatkan softfilenya

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment